In recent days, Allogene Therapeutics reported encouraging clinical trial outcomes and new FDA designations for its off‑the‑shelf CAR T‑cell therapies, while analysts cited a supportive sector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results